logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria

Oladimeji O, Isaakidis P, Obasanya OJ, Eltayeb O, Khogali MA, Van der Bergh R, Kumar AMV, Hinderaker SG, Abdurrahman ST, Lawson L, Cuevas LE
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Nigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.

Countries

Nigeria

Subject Area

antibiotic resistancetuberculosisSORT-ITantimicrobial resistanceHIV/AIDS

Languages

English
DOI
10.1371/journal.pone.0094393
Published Date
10 Apr 2014
PubMed ID
24722139
Journal
PLOS One
Volume | Issue | Pages
Volume 9, Issue 4
Issue Date
2014-04-10
Dimensions Badge